Full Press Release Details
Allogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T Candidate Targeting CD70 for the Treatment of Renal Cell Carcinoma, at AACR's Annual Meeting and in Cancer Research Journal.
ALLO
Allogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T Candidate Targeting CD70 for the Treatment of Renal Cell Carcinoma, at AACR's Annual Meeting and in Cancer Research Journal
Key Takeaway: Allogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T Candidate Targeting CD70 for the Treatment of Renal Cell Carcinoma, at AACR's Annual Meeting and in Cancer Research Journal